Walrycin B is primarily investigated for its potential antimicrobial and antitumor activities. It shows promise in inhibiting the growth of certain drug-resistant bacterial strains, making it a candidate for development in anti-infective therapies. Additionally, studies indicate that Walrycin B may interfere with cancer cell proliferation, particularly in solid tumors, by targeting specific cellular pathways involved in cell cycle regulation. Its unique structure also makes it a subject of interest in the design of novel derivatives for pharmaceutical research. Work is ongoing to improve its bioavailability and reduce potential toxicity for therapeutic use.